Peringkat dalam Saham
#24454
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Kapitalisasi Pasar
$60.45M
Perubahan (1 tahun)
-12.06%
Perdagangan Lytix Biopharma AS (LYTIX)
Harga LYTIX dengan kapitalisasi pasar B
Kapitalisasi pasar dari Lytix Biopharma AS(LYTIX)
Kapitalisasi Pasar: $60.45M
Per August 2026, Lytix Biopharma AS memiliki kapitalisasi pasar sebesar $60.45M. Ini menjadikan Lytix Biopharma AS sebagai perusahaan 24454th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Lytix Biopharma AS dari 2021 hingga 2026
LYTIX dibandingkan dengan 5 teratas stocks paling populer
| Harga LYTIX |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.221T
|
+8,636,190.89%
|
|
|
|
|
$4.567T
|
+7,554,793.23%
|
|
|
|
|
$4.162T
|
+6,885,484.73%
|
|
|
|
|
$3.598T
|
+5,951,905.89%
|
|
|
|
|
$2.782T
|
+4,601,788.39%
|
